# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
1 | 08-12-2024 | 06-30-2024 | 10-Q | |
2 | 05-13-2024 | 03-31-2024 | 10-Q | |
3 | 03-05-2024 | 12-31-2023 | 10-K | |
4 | 11-13-2023 | 09-30-2023 | 10-Q | |
5 | 08-28-2023 | 06-30-2023 | 10-Q |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Net Loss: Net loss for the second quarter of 2024 was $33.8 million, compared to the net loss for the second quarter of 2023 wh...
10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeut...
Interim clinical data from APG777 Phase 1 healthy volunteers study exceeded all trial objectives and achieved a half-life of ap...
Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing differentiated biologics for the trea...
B of A Securities analyst Geoff Meacham initiates coverage on Apogee Therapeutics (NASDAQ:APGE) with a Buy rating and announ...
As of March 14, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum a...